Pfizer’s shares fell sharply on Tuesday as global markets rose steadily. Analysts cut their ratings on the firm over weak drug prospects. Some investors remain concerned the pipeline looks thin and leadership remains unsettled.
But Pfizer earned a key approval: the first CDK4/6 maintenance therapy for advanced HER2-positive breast cancer. Still, the stock losses outweighed the good news. Offices in Midtown Manhattan cleared out after beams gave way, raising collapse concerns.